Patent ID: 11918605
Assignee: MYELOID THERAPEUTICS, INC.
Field: Pharmaceuticals (Chemistry)
Classification: CPC C  A | IPC A  C

Claim 0:
1. A pharmaceutical composition comprising:
(a) an ex vivo population of cells comprising CD14+/CD16+ cells, wherein the CD14+/CD16+ cells comprise a recombinant polynucleic acid with a sequence encoding a chimeric antigen receptor (CAR), wherein the CAR comprises (i) an anti-HER2/neu binding domain and a CD8a hinge domain; (ii) a transmembrane domain; and (iii) an intracellular domain containing a CD3 zeta intracellular signaling domain; and
(b) a pharmaceutically acceptable excipient;
wherein the pharmaceutical composition stimulates tumor killing by T cells in a subject with cancer when the pharmaceutical composition is administered to the subject.